Assertio Holdings Inc (ASRT)Healthcare | Drug Manufacturers - Specialty & Generic | Lake Forest, United States |
USD
|
Hot Take ↕ | Oct. 10, 2026, 8:39 a.m. UTC
The investment thesis here is entirely driven by the imminent corporate restructuring rather than the company's operational performance. The stock has effectively been removed from the Nasdaq listing, signaling a severe lack of compliance with market standards, yet it is simultaneously surging on news of a definitive cash acquisition by Zydus Worldwide at $23.50 per share. With a tender offer acceptance rate already exceeding 66%, the probability of this deal closing is extremely high, creating a powerful, albeit temporary, bullish case for capital preservation and immediate gains. However, looking past the takeover premium, the underlying business is fundamentally broken: revenue has collapsed by 62.5%, the company is burning cash with negative operating flows, and profitability is nonexistent with a massive loss margin. The balance sheet is fragile, and there is no history of dividends or sustainable growth. While the short-term outlook is overwhelmingly positive due to the pending merger, the long-term future of the entity as currently constituted is non-existent, making it a pure event-driven trade with zero intrinsic value beyond the buyout price. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 53.302 |
| Revenue per Share | 15.92 |
| Market Cap | 151,861,232 |
| Forward P/E | 9.11 |
| Beta | 0.53 |
| Profit Margins | -34.94% |
| Website | https://www.assertiotx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 1.406924 |
| Address1 | 100 South Saunders Road |
| Address2 | Suite 300 |
| All Time High | 2,024.4 |
| All Time Low | 7.705499 |
| Ask | 23.5 |
| Ask Size | 100 |
| Audit Risk | 3 |
| Average Daily Volume10 Day | 117,665 |
| Average Volume | 322,528 |
| Average Volume10Days | 117,665 |
| Beta | 0.531 |
| Bid | 20.19 |
| Bid Size | 100 |
| Board Risk | 3 |
| Book Value | 11.735 |
| City | Lake Forest |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Currency | USD |
| Current Price | 23.5 |
| Current Ratio | 1.822 |
| Date Short Interest | 1,780,012,800 |
| Day High | 23.5 |
| Day Low | 23.48 |
| Debt To Equity | 53.302 |
| Ebitda | 3,827,000 |
| Ebitda Margins | 0.03746 |
| Enterprise To Ebitda | 31.514 |
| Enterprise To Revenue | 1.181 |
| Enterprise Value | 120,605,232 |
| Exchange | NGM |
| Exchange Timezone Name | UTC |
| Fax | 510 744 8001 |
| Fifty Day Average | 21.9949 |
| Fifty Two Week High | 23.5 |
| Fifty Two Week Low | 8.61 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,781,616,600 |
| Float Shares | 6,264,825 |
| Forward Eps | 2.58 |
| Forward P E | 9.108527 |
| Free Cashflow | 7,750,750 |
| Full Time Employees | 53 |
| Fullday Change | 23.5 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 23.5 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,780,531,200 |
| Gross Margins | 0.70332 |
| Gross Profits | 71,850,000 |
| Held Percent Insiders | 0.01968 |
| Held Percent Institutions | 0.29285 |
| Implied Shares Outstanding | 6,462,180 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,766,707,200 |
| Last Split Factor | 1:15 |
| Long Business Summary | Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois. |
| Long Name | Assertio Holdings Inc |
| Market Cap | 151,861,232 |
| Max Age | 86,400 |
| Message Board Id | finmb_363049 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -35,690,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Number Of Analyst Opinions | 3 |
| Open | 23.48 |
| Operating Cashflow | -7,081,000 |
| Operating Margins | -1.85946 |
| Overall Risk | 1 |
| Peg Ratio | 0.89 |
| Phone | 224 419 7106 |
| Previous Close | 0.0 |
| Price Hint | 2 |
| Price To Book | 2.0025566 |
| Price To Sales Trailing12 Months | 1.4865329 |
| Profit Margins | -0.34936002 |
| Quick Ratio | 1.453 |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.33333 |
| Regular Market Day High | 23.5 |
| Regular Market Day Low | 23.48 |
| Regular Market Open | 23.48 |
| Regular Market Previous Close | 0.0 |
| Regular Market Volume | 269,201 |
| Return On Assets | -0.057129998 |
| Return On Equity | -0.38759 |
| Revenue Growth | -0.625 |
| Revenue Per Share | 15.92 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 6,462,180 |
| Shares Percent Shares Out | 0.051799998 |
| Shares Short | 334,922 |
| Shares Short Previous Month Date | 1,777,507,200 |
| Shares Short Prior Month | 289,282 |
| Short Name | Assertio Holdings, Inc. |
| Short Percent Of Float | 0.0525 |
| Short Ratio | 0.71 |
| State | IL |
| Symbol | ASRT |
| Target High Price | 28.0 |
| Target Low Price | 21.8 |
| Target Mean Price | 24.43333 |
| Target Median Price | 23.5 |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 71,569,000 |
| Total Cash Per Share | 11.075 |
| Total Debt | 40,313,000 |
| Total Revenue | 102,158,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | NaN |
| Trailing Eps | -5.55 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 14.897315 |
| Underlying Symbol | ASRT |
| Uuid | b0b71d5e-e500-3f56-bb27-7703d923929a |
| Volume | 269,201 |
| Website | https://www.assertiotx.com |
| Zip | 60,045 |